Vertex Pharmaceuticals Files Routine 8-K
Ticker: VRTX · Form: 8-K · Filed: Jun 27, 2024 · CIK: 875320
Sentiment: neutral
Topics: corporate-filing, regulatory
Related Tickers: VRTX
TL;DR
VRTX filed an 8-K, looks like standard corporate housekeeping, no major news.
AI Summary
On June 27, 2024, Vertex Pharmaceuticals Incorporated filed an 8-K report. The filing indicates no specific material events or transactions requiring immediate disclosure under the standard 8-K items. It appears to be a routine filing or an update related to ongoing corporate activities.
Why It Matters
This filing suggests no significant new developments or material changes for Vertex Pharmaceuticals as of June 27, 2024, which could impact investor sentiment or strategic outlook.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report with no disclosed material events, indicating a lack of immediate significant risk or change.
Key Numbers
- 000-19319 — SEC File Number (Identifies Vertex Pharmaceuticals' filings with the SEC.)
- 04-3039129 — IRS Employer Identification No. (Vertex Pharmaceuticals' tax identification number.)
Key Players & Entities
- Vertex Pharmaceuticals Incorporated (company) — Registrant
- 0000875320-24-000178 (filing_id) — Accession Number
- June 27, 2024 (date) — Date of Report
- Massachusetts (location) — State of Incorporation
- 50 Northern Avenue Boston, Massachusetts 02210 (address) — Principal Executive Offices
FAQ
What specific event triggered this 8-K filing?
The filing does not specify a particular event, suggesting it may be a routine filing or related to ongoing corporate activities rather than a material event.
Are there any new financial disclosures in this report?
This 8-K filing, as presented, does not contain specific financial disclosures beyond standard company identification and address information.
What is the significance of the 'Other Events' item information?
The 'Other Events' item in an 8-K is used for disclosing material events that do not fit into the other specific categories, but this filing does not detail any such events.
When was Vertex Pharmaceuticals Incorporated incorporated?
Vertex Pharmaceuticals Incorporated was incorporated in Massachusetts, as indicated by the filing.
What is the primary business of Vertex Pharmaceuticals?
Vertex Pharmaceuticals is classified under the SIC code 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 933 words · 4 min read · ~3 pages · Grade level 14 · Accepted 2024-06-27 16:05:51
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 Par Value Per Share VRTX The Nasdaq G
- $5.0 billion — nces, Inc. ("Alpine") for approximately $5.0 billion in cash (the "Alpine Acquisition"). Ver
- $4.4 billion — ent ("AIPR&D") expense of approximately $4.4 billion during the second quarter of 2024. The
- $200 million — equity incentive plans of approximately $200 million during the second quarter of 2024. This
Filing Documents
- vrtx-20240627.htm (8-K) — 25KB
- 0000875320-24-000178.txt ( ) — 147KB
- vrtx-20240627.xsd (EX-101.SCH) — 2KB
- vrtx-20240627_lab.xml (EX-101.LAB) — 21KB
- vrtx-20240627_pre.xml (EX-101.PRE) — 12KB
- vrtx-20240627_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. As previously disclosed, on May 20, 2024, Vertex Pharmaceuticals Incorporated ("Vertex") completed its acquisition of Alpine Immune Sciences, Inc. ("Alpine") for approximately $5.0 billion in cash (the "Alpine Acquisition"). Vertex expects to account for the Alpine Acquisition as an asset acquisition. Based on this determination, Vertex expects to record a one-time, non-deductible, Acquired In-Process Research & Development ("AIPR&D") expense of approximately $4.4 billion during the second quarter of 2024. The AIPR&D expense will impact reported GAAP and non-GAAP operating expenses and GAAP and non-GAAP net income for the second quarter and full year 2024, and related financial guidance for full year 2024. In addition, Vertex expects to incur transaction-related compensation expense associated with acceleration of unvested awards pursuant to Alpine's equity incentive plans of approximately $200 million during the second quarter of 2024. This transaction-related compensation expense will impact Vertex's reported GAAP operating expenses and GAAP net income for the second quarter and full year 2024, and related financial guidance for full year 2024. Vertex continues to expect to absorb Alpine's non-GAAP research and development ("R&D") and selling, general and administrative ("SG&A") expenses for the remainder of 2024 in the related operating expense guidance range provided on May 6, 2024. This Current Report on Form 8-K contains forward-looking statements that are subject to risks, uncertainties and other factors including, without limitation, statements regarding the expected accounting treatment of the Alpine Acquisition and the anticipated impact of such accounting treatment on Vertex's related financial guidance. While Vertex believes the forward-looking statements contained in this communication are accurate, these forward-looking statements represent the beliefs of Vertex only as of the date of this communication, and there are a num
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VERTEX PHARMACEUTICALS INCORPORATED (Registrant) Date: June 27, 2024 /s/ Jonathan Biller Jonathan Biller Executive Vice President, Chief Legal Officer